This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Staffan P. E. Sylvan, MD; Ulla B. Hellstrom, PhD
Karolinska Hospital Stockholm, Sweden

Hartmut Hampl, PhD; Hans-Peter Kapprell, PhD; Hugo Troonen, MD
Abbott GmbH Diagnostica Wiesbaden-Delkenheim, Germany

JAMA. 1995;273(5):377-378.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In industrialized countries, it is generally believed that only international travelers face the threat of hepatitis E virus (HEV) infection.¹ Recently, Kuwada et al reported that three patients with fulminant hepatitis, all with features of autoimmune hepatitis, had raised IgG anti-HEV antibody titers.² However, in the 6 months before their hospital admission, none of these patients had traveled to a region of the world where HEV was endemic. This finding prompted us to investigate the presence of HEV antibodies in serum samples from 13 patients with autoimmune—chronic autoimmune hepatitis (AI-CAH) (all positive for antinuclear or anti—smooth muscle antibodies), nine patients with cryptogenic hepatitis (seronegative autoimmune hepatitis), and three patients with primary biliary cirrhosis who were all positive for antimitochondrial antibodies. Serological test results for ongoing or past infection with hepatitis A, B, C, or D virus were negative in all patients. To detect anti-HEV IgG, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?